Intracranial hemorrhage occurs more commonly after carotid stenting than carotid endarterectomy Study design: This is a retrospective population-based study of patients comparing the rate of postprocedure intracranial hemorrhage (ICH) after carotid artery stenting (CAS) vs carotid endarterectomy (CEA) in Ontario, Canada between 2002 and 2015.
Key findings: A total of 16,688 patients underwent CEA (86%) or CAS (14%). ICH developed within 90 days in 0.85% after CAS vs 0.42% after CEA (P < .0001). Although patients who underwent CAS were more likely to have comorbidities, symptomatic carotid disease or cardiac disease and taking antiplatelet agents or warfarin preprocedure, the results were consistent after adjusting for these factors. The 6-month mortality rate for patients who suffered ICH was 43%.
Conclusion: Carotid artery stenting is associated with a higher risk of intracranial hemorrhage compared to carotid endarterectomy.
Commentary: Hyperperfusion syndrome and ICH are associated with systemic hypertension after carotid revascularization. Hyperperfusion typically occurs within 12 hours after CAS (likely due to baroreceptor activation at the time of stent deployment) compared to peaking several days postoperatively after CEA. This large retrospective cohort study found that the risk of ICH was significantly higher after CAS (0.85%) than CEA (0.42%). However, this difference may not be clinically significant. This discrepancy in ICH was not due to differences in preprocedure antiplatelet or anticoagulant. Many factors were not assessed, such as the degree of contralateral disease, plaque characteristics, and, most importantly, postprocedure dual antiplatelet therapy, which the authors agree was almost certainly higher in stented patients. A review of patients who underwent CEA in the Vascular Quality Initiative showed that dual therapy with aspirin and clopidogrel was associated with increased reoperation for bleeding (P ¼ .003), but the risk of ICH was not addressed.
1 Nonetheless, use of dual therapy was associated with decreased risk of perioperative stroke compared to aspirin alone (P ¼ .03) and the overall stroke risk was very low. There may not be much interventionalists can do to reduce the risk of this devastating complication after CAS, which may be due to the required use of clopidogrel before and after this intervention. Key findings: A total of 556 patients underwent femoropopliteal angioplasty with 461 (82%) performed via AA. AA patients had a lower body mass index (26 vs 29; P ¼ .005). No significant difference was seen in periprocedural (15.8% AA vs. 11.6% RA) or access site complications (3.7% AA vs. 1.1% RA). There was less need for a closure device (40.3% AA vs 73% RA; P < .01), less contrast (94 mL AA vs 114 mL RA; P < .001), and less radiation (3487 cGy cm 2 AA vs 9697 cGy cm 2 RA; P < .001) with AA. AA was also associated with greater technical success (83.8%) of treating the lesion than RA (73.3%; P ¼ .002).
Conclusion: Ipsilateral antegrade femoral access is associated with higher technical success and reduced contrast and radiation doses, with no significant difference in complications compared to contralateral retrograde femoral arterial access.
Commentary: There are four reasons contralateral RA is favored for lower extremity arterial endovascular interventions compared to AA. First, imaging of the aortoiliac arteries to rule out occlusive disease is possible with RA and not with AA. Second, the authors agree in the manuscript that RA is technically easier to perform. Third, the authors agree RA has a favorable orientation for superficial femoral artery selection. Fourth, bleeding complications and the need for emergent femoral artery repair are lower with contralateral RA. The authors found that AA was associated with less contrast and radiation than RA. But, to rule out proximal aortoiliac occlusive disease, they must either obtain computed tomography angiography, which requires more contrast and radiation than an aortoiliac arteriogram or rely on noninvasive studies. From a technical stand point, it is impossible to perform AA in very obese patients, even after taping the pannus proximally. Even the authors preferred RP in these patients as evidence by a lower body mass index in the AA group. The authors also favored RA for emergency cases (Why? It's easier and faster). AA has a definite disadvantage in terms of orientation for superficial femoral artery cannulation. Lastly, the authors did not find significant differences in periprocedural (15.8% AA vs 11.6% RA) or access site complications (3.7% AA vs 1.1% RA), but there certainly was a trend showing higher complications with AA (most likely a type II statistical error). The authors used closure devices more commonly with RA, but this was a self-fulfilling prophecy. In the manuscript, they stated they used manual pressure for 4F sheaths and closure devices for 6F sheaths but noted 4F sheaths were most commonly used for AA and 6F sheaths for RA. The authors have not convinced me, and hopefully not the reader, that AA is the preferred approach for lower extremity endovascular interventions.
